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Background: Application of nanoenzymes, based on D-amino acid oxidase (DAAO) 
conjugated to magnetic nanoparticles (NPs), as anticancer system requires improvement 
of the synthesis protocol and in vivo distribution evaluation. Results: A new and more 
efficient synthesis via EDC-NHS produced an Fe3O4NP-APTES-DAAO system with a 
specific activity of 7 U/mg NPs. IR spectroscopy showed that all Fe3O4 NP sites are 
saturated with APTES and all available NH2 sites with DAAO. The acute cytotoxicity 
of the new system does not differ from that of the previous one. In vivo experiments 
showed that the system did not cause adverse effects, cross the brain–blood barrier 
and accumulate in the heart. Conclusions: Our results support the possibility to use 
enzymes conjugated to magnetic NPs for cancer treatment. Besides, we think that 
enzymes and other biological molecules efficiently conjugated to magnetic NPs might 
constitute a category of ‘bionanoparticles’ to be exploited, not only in medical, but 
also in industrial biotechnology.
Lay abstract: We have linked magnetic nanoparticles to D-amino acid oxidase, an 
enzyme capable of producing, in the presence of its substrate, reactive oxygen species. 
The scope is to use the magnetic properties of the enzyme-nanoparticle system to 
direct it to a desired area where its cytotoxicity can be controlled by the addition of 
exogenous substrate. Besides the possible applications in cancer therapy, we think 
that enzymes and other biological molecules linked to magnetic nanoparticles might 
also be exploited in industrial biotechnology.
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Nanoparticles (NPs) and other nanomateri-
als permeate several areas of our everyday life. 
In industrial applications, they have become 
indispensable components of catalysts [1], 
sensors [2] and photovoltaic devices [3]. 
Unfortunately, the same peculiar properties 
that make nanomaterials so attractive may 
create potentially new and largely undefined 
risks for human health. NPs, in effect, are 
capable to cross biological barriers [4–6] and 
are readily taken up by cells [7] where they 
can exert their toxicity. However, NPs have 
also found widespread use in the biomedi-
cal field, as nanovaccines, nanodrugs and 
diagnostic imaging tools [8]. The increasing 
number of nanotechnology patents related to 
healthcare reflects the rapid expansion of this 
pioneering industry [9].
The impact of nanobiotechnology on 
oncology is huge and includes fields ranging 
from discovery of tumor biomarkers to devel-
opment of devices for cancer surgery [10,11]. In 
particular, drug-delivery, the most explored 
field, aims to design carriers that deliver 
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drugs more precisely to tumor cells and maintain them 
at therapeutic concentrations over a long period [12]. 
Besides considerable progress in cancer therapy and 
the many anticancer drugs available, the treatment of 
cancer has still a lot of side effects [13] and NPs could be 
an efficient alternative to conventional therapies, serv-
ing as carrier systems capable of enhancing efficacy, 
while simultaneously reducing side effects. Magnetic 
NPs can be functionalized with anticancer drugs and 
guided along an externally placed magnet into the 
tumor [14]. Moreover, magnetic NPs can produce heat 
through various energy losses under an external alter-
nating magnetic field, causing cancer destruction by 
hyperthermia [15–20].
In a previous work [21], we set up the synthesis of an 
NP-enzyme system for cancer therapy via glutaralde-
hyde. The system (Fe
3
O
4
-APTES-DAAO) was based 
on iron oxide magnetic NPs conjugated to the ROS-
producing enzyme D-amino acid oxidase from Rhodo-
torula gracilis (RgDAAO, EC 1.4.3.3). Fe
3
O
4
-APTES-
DAAO aims to combine the advantages of magnetic 
NPs (low acute toxicity, specific target by a magnetic 
field, ability to cross biological barriers) with those of 
RgDAAO (no acute toxicity, easy modulation of the 
activity, hence of ROS generation). The system can be 
intravenously injected and addressed by an external 
magnetic field in the tumor area, where D-amino acids 
(naturally present or externally injected) act as sub-
strate for the enzyme, causing H
2
O
2
 production and 
tumor cell death by apoptosis.
This work is on continuing the research of using 
magnetic NPs conjugated to DAAO for the potential 
treatment of cancer, a step forward in the possible real-
ization of this clinical technique. To this aim, we pres-
ent a new and more efficient synthesis of this system 
via EDC-NHS and the characterization by infra red 
(IR) spectroscopy of the two systems resulting from 
the old and the new methods of synthesis. Moreover, 
we have analyzed the in vivo distribution as well as the 
acute toxicity of the new system after single intrave-
nous administration in mice. We have also realized 
that enzymes conjugated to magnetic NPs could be of 
interest also for industrial purposes [22].
Materials & methods
Coating of magnetic NPs with APTES
Fe
3
O
4
 NPs were functionalized according to the pro-
tocol of Bava et al. [21]. Briefly, 150 mg of Fe
3
O
4
 NPs 
(Sigma, cat. number 637,106) were ultrasonicated in 
10 ml of H
2
O MilliQ for 15 min. A solution of 5 ml 
APTES (2% v/v, Sigma cat. number A3648) in H
2
O 
MilliQ was then added and the reaction was main-
tained under mechanical stirring for 5 h at 50°C. 
Fe
3
O
4
-APTES were then separated from unbound 
APTES by a commercial parallelepiped neodymium 
magnet (Webcraft GmbH, Uster, Switzerland; Ni-
Cu-Ni plated; magnetization: N45; size: 30 × 30 × 15 
mm), washed several times with water and anhydrifi-
cated with ethanol overnight. Fe
3
O
4
-APTES were sus-
pended again in water, ultrasonicated for 30 min and 
left at room temperature for 1 h, isolated and dried at 
50°C overnight.
Synthesis of Fe3O4NP-APTES-DAAO
Four milligrams of Fe
3
O
4
NP-APTES were suspended 
by sonication for 15 min with 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (EDC, Sigma cat. number 
03450) and N-hydroxysuccinimide (NHS, Sigma, cat. 
number 130,672) in 3:2 (w/w) ratio in 5 mM sodium 
pyrophosphate (NaPPi) buffer, pH 8.5. Two hundred 
and fifty micrograms of recombinant RgDAAO [19] 
were added and the reaction was carried out for 4 h at 
4°C using a rotating plate tube stirrer. Subsequently, 
Fe
3
O
4
-APTES-DAAO were collected by a magnet and 
washed twice with 1 ml of 5 mM NaPPi pH 8.5. The 
supernatant was stored for further analysis.
DAAO activity assay
The activity of Fe
3
O
4
-APTES–DAAO was determined 
by measuring the absorbance increase accompanying 
the H
2
O
2
-induced oxidation of o-dianisidine [20]. One 
DAAO unit corresponds to the amount of enzyme that 
converts 1 μmol of substrate per min at 25°C and at 
0.253 mM oxygen concentration [23,24]. The standard 
assay mixture contained 890 μl of 100 mM D-alanine 
in 100 mM NaPPi buffer, pH 8.5 buffer, 100 μl of 
3.2 mg/ml o-dianisidine in water, 10 μl of 0.4 mg/ml 
horseradish peroxidase in 100 mM NaPPi buffer, pH 
8.5 buffer and 10 μl of 0.4 mg/ml Fe
3
O
4
NP-APTES-
DAAO in the same buffer. The reaction was initiated 
by the addition of the enzyme and the absorbance 
increase was monitored at 440 nm for 1 min using an 
UV-Vis Jasco V-560 spectrophotometer.
IR analysis
Fe
3
O
4
NP-APTES-DAAO were characterized by IR 
analysis in different conditions. Samples (disks of 2 
cm2 area) were placed in a quartz cell equipped with 
KBr windows. A movable quartz sample holder allows 
to adjust the pellet in the infrared beam for spectra 
recording and to displace it into a furnace at the top 
of the cell for thermal treatment. The cell was con-
nected to a vacuum line for evacuation (P
residual
 = ∼10–6 
torr) and for the introduction of gases into the infra-
red cell. Spectra were recorded at room temperature. 
The addition of well-known doses of gas in the cell was 
possible via a pressure gauge for the control of the gas 
pressure. A Nicolet Nexus spectrometer equipped with 
www.future-science.com 10.4155/fso.15.67future science group
New synthesis & biodistribution of the D-amino acid oxidase-magnetic nanoparticle system    Research Article
a Mercury Cadmium Telluride (MCT) cryodetector 
and an extended KBr beam splitter was used for the 
acquisition of spectra in the 600–5500 cm-1 range. IR 
spectra are absorption spectra and the notation used is 
a.u. for absorption units. The resolution of the spectra 
was 4 cm-1, and 256 scans were accumulated for each 
spectrum.
Three kinds of experiments have been performed: 
first the samples have been dispersed in the KBr, then 
on the surface of a silica pellet; finally on a silicon disk. 
In details: a wafer containing 98 mg of KBr has been 
pressed at 4 tons/cm2, together with ∼2 mg of the tar-
geted sample; a wafer of 20 mg silica has been casted 
mixing in its center ∼6–7 mg of sample, then pressed 
to 2 tons /cm2 and ∼2 mg of powder have been dis-
persed on the surface of a 2 cm2 silicon disk by the help 
of a spot of ethanol.
Dynamic light scattering (DLS) analysis
Fe
3
O
4
, Fe
3
O
4
-APTES and Fe
3
O
4
-APTES-DAAO NPs 
were analyzed at concentrations of 250, 25 and 2.5 μg/
ml in water. Sample dilutions were done in order to 
analyze the effect of concentration on NP aggregation. 
Each measurement was preceded by an equilibration 
time of 90 s. Analyzes were performed with Zetasizer 
Nano ZS90 (Malvern, UK) instrument. Measures 
were reported as scattering intensity in function to 
diameter.
Cell viability
SKOV-3 cell lines were maintained as adherent cells 
in RPMI1640 medium (supplemented with 10% fetal 
bovine serum, 1% L-glutamine and 1% penicillin/
streptomycin solution) at 37°C in a humidified 5% 
CO
2
 atmosphere. Cells were passaged as needed using 
0.25% trypsin–EDTA.
Cell viability was determined as ATP content by 
using the CellTiter-Glo Luminescent Cell Viability 
Assay according to the manufacturer’s instruction. In 
details, 1 × 104 cells were seeded into 96-well assay 
plates and cultivated for 24 h at 37°C in 5% CO
2
 to 
equilibrate and become attached prior to the treat-
ment. Cells were then exposed to increasing amounts 
of Fe
3
O
4
-APTES-DAAO, in presence or not of its 
substrate, for 24 h in a final volume of 100 μl. Fol-
lowing the treatment, plates were equilibrated for 30 
min at room temperature and 100 μl of CellTiter-
Glo Reagent was then added to each well. Plates were 
shaken for 2 min and left at room temperature for 10 
min prior to the recording of luminescent signals using 
the Infinite F200 plate reader (Tecan Group, Män-
nedorf, Switzerland). The experiments were performed 
in triplicate. Cell viability, expressed as ATP content, 
was  normalized against control values.
In vivo studies
To evaluate the biodistribution and acute toxicity of 
NPs, two in vivo studies were performed. In both 
experiments, male CD-1(ICR) mice of 4–5 weeks were 
purchased from Charles River (Calco, Italy). They 
were acclimated to the environment for a week prior to 
the initiation of the study, with free access to water and 
a standard pellet diet ad libitum. The environmental 
conditions were set at a temperature of 22 ± 2°C, relative 
humidity of 55 ± 10% and a 12 h light:dark cycle. The 
mice (n = 3) were intravenously injected with a single 
dose of Fe
3
O
4
-APTES-DAAO (in the first experiment 
100 mg/kg bodyweight (bw) of NPs in NaCl 0.9%, 
and in the second experiment 20 mg/kg bw of NPs 
in NaPPi buffer at pH 7.4) and sacrificed 24 h after 
the treatment. The control groups were treated with 
the corresponding vehicle (NaCl 0.9% or NaPPi buf-
fer). Immediately after the treatment and the following 
hours, the general health and behavior of mice were 
monitored. The bodyweight of each mouse was mea-
sured before treatment and at sacrifice. The experiment 
was performed in accordance with the Italian Laws 
(D.L. 116/92 and following additions), which enforce 
EU 86/609 Directive (Council Directive 86/609/EEC 
of 24 November 1986, on the approximation of laws, 
regulations and administrative provisions of the mem-
ber states regarding the protection of animals used for 
experimental and other  scientific purposes).
Sacrifice, sampling & pathological examination 
procedures
Mice were euthanized at 24-h post-treatment accord-
ing to standard procedures and in compliance with 
local regulations, and underwent complete necropsy. 
Liver, spleen and kidney were weighed and the rela-
tive organ weight (wet organ/total bodyweight) was 
 calculated.
Liver, kidney, spleen, lung, heart, testis and brain 
were fixed in 10% neutral-buffered formalin, and 
routinely processed for paraffin embedding. Four 
micrometer sections from each tissue were stained with 
hematoxylin and eosin (HE) and Perls iron stain [25], 
and evaluated under a light microscope. Quantitative 
evaluation of iron deposits in Perls iron stained sections 
was performed by digital image analysis: area of Perls 
staining was measured in three 200× microscopic fields 
using the ImageJ analysis program [26], and the percent-
age of Perls positive area per field was then  calculated.
For immunofluorescence, liver sections were immu-
nostained with rabbit monoclonal anti-Iba1 antibody 
(Wako Chemicals, VA, USA, cat. number 019–19741), 
a pan-macrophage marker [27]. Secondary antibody, 
Alexa Fluor® 555 F(ab’)2 Fragment of Goat Anti-Rab-
bit IgG (H+L; Life Technologies Europe BV, Monza, 
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Italy, cat. number A-21430) was then added. Immuno-
fluorescently labeled sections were acquired with the 
Leica TCS SP5 confocal microscope (Leica Microsys-
tems GmbH, Wetzlar, Germany). The Alexa555 fluo-
rophore was excited with the 561 nm laser line and the 
emitted fluorescence (570–700 nm) acquired with a 
63×/1.4 oil immersion objective (Leica Microsystems, 
GmbH). Nuclei were visualized by DAPI staining 
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Figure 1. IR spectra of Fe3O4-APTES-DAAO prepared via glutaraldehyde (red) and via EDC/NHS (blue). Samples 
were dispersed in KBr (2% w/w).
Figure 2. IR spectral subtraction. Spectrum of Fe3O4-APTES-DAAO prepared with the first method minus those 
prepared with the second method.
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(405 nm laser line excitation, 415–500 nm acquisition 
window). Iron aggregates were visualized by reflection 
of light at 561 nm.
Statistical analysis
Data were analyzed using GraphPad Prism version 5.0 
(GraphPad Software, CA, USA). Statistical analyses 
Figure 3. IR spectra of samples dispersed in silica. Bottom: in blue, subtraction of glutaraldehyde and EDC/NHS samples, in cyan, 
magenta and green spectra of glutaraldehyde samples after NO and CO adsorption. Top: EDC/NHS samples spectra after CO 
adsorption. Arrow indicates peak at 1508 cm-1.
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Figure 4. Spectra in the top refer to NO adsorption (10 and 18 torr at the equibrium) on the glutaraldehyde 
sample. Spectrum in the bottom is the difference before and after the adsorption of CO on the EDC/NHS sample.
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of the results were performed using Mann–Whitney 
U test to compare the experimental conditions with 
controls. p-values <0.05 were considered statistically 
significant.
Results
Activity analysis
RgDAAO was conjugated to Fe
3
O
4
-APTES by means 
of EDC and NHS. Under best experimental condi-
tions, the amount of enzyme bound to NPs, deter-
mined as the difference between the protein amount 
added and that recovered in the supernatant, is close 
to 100%, with an enzymatic activity of approximately 
7 U/mg NP.
IR characterization
The spectra of Fe
3
O
4
-APTES-DAAO prepared with 
the two methods (the old one via glutaraldehyde and 
the new one presented here), dispersed in the KBr (to 
identify the structural components), are reported in 
Figure 1. The two spectra are similar. At the highest 
wavenumbers, we can observe the stretching of the OH 
groups of water adsorbed on KBr, likely 3425 cm-1. In 
the 3300–3000 cm-1 region, the ν(NH) vibrations are 
observed; they correspond to the NH
2
 moieties pres-
ent in the organic ligand. The corresponding bending 
mode is at 1650–1640 cm-1 and 1546 cm-1, partially 
overlapped with the δ(HOH) of water at ∼1630 cm-
1. Below 800 cm-1, only structural (saturated) bands 
are visible, containing bending, twisting and rocking 
modes, together with the stretches of M-O bonds. The 
other bands (in the 1600–1000 cm-1 region) are due to 
C-C and C-O bonds, while those in the 3000–2800 
cm-1 interval to C-H stretches, difficult to be discrimi-
nated at this step. Interestingly, no bands at ∼1745 
cm-1, typical of the C=O bonds of the aldehydes, can 
be distinguished. Performing a spectral subtraction 
(Figure 2) we can better scrutinize the differences in the 
two compounds: the vibrations associated to the NH
2
 
species almost disappear in the compound prepared via 
EDC/NHS, as indicated by the bands in positive in 
the difference spectrum (3400–3000 cm-1 region, plus 
1649 and 1546 cm-1 peaks) and by the absence of the 
corresponding bands in the blue spectrum in Figure 1. 
A very weak feature appears at 1735 cm-1, accounting 
for aldehyde typical vibration.
Figure 5. Spectra of samples collected on a silicon wafer. A and B refer to glutaraldehyde samples while C and D 
refers to EDC/NHS samples.
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When dispersing the samples on silica as a support 
(Figure 3), the observed bands essentially deal with OH 
groups on silica (3746 cm-1) and adsorbed water (∼3450 
and 1630 cm-1). The features at 1972 and 1867 cm-1 are 
overtones and combination bands of the silica frame-
work (massif below 1300 cm-1) (spectrum blue, Figure 3). 
The sample has been probed by adsorption of CO and 
NO, two molecules adapted to reveal (and quantify) the 
presence of coordinatively unsaturated iron cations [28]. 
After CO or NO adsorptions, no remarkable differences 
can be distinguished especially on the glutaraldehyde 
sample (Figure 3, spectra cyan, magenta and green). In 
the case of the EDC/NHS sample, a weak component 
appears at 1508 cm-1 (Figure 3, spectrum red, red arrow), 
which cannot be related directly with the probe mol-
ecules. Eventually, it could be ascribed to CO interac-
tions with some accessible ligand in the organic part, 
inducing a shift in a C–C or C–O vibration. Subtrac-
tion spectra (Figure 4) confirm that no effect of probe 
molecule adsorption can be detected, so suggesting the 
absence of unsaturated iron moieties.
Spectra of the samples characterized after deposi-
tion on a silicon wafer (to discard any potential inter-
action with a support) are reported in Figure 5. Besides 
the interference fringes due to the specular surfaces 
of the Si disks, we can observe only bands due to the 
organic ligands, already mentioned above. Comparing 
the spectra during the adsorption of CO as probe mol-
ecule and after evacuation (B and A for glutaraldehyde, 
respectively, and C and D for EDC/NHS), we can-
not observe any difference, if we exclude the changes 
in the baseline, irrelevant for the present study. Even, 
this latter approach for the sample analysis seems less 
appropriate, providing spectra of relatively low quality.
DLS analysis
In all samples, production of NP aggregates of 300 nm 
or more is evident. The size of the aggregates varies 
with the dilution: at increased dilution the diameter 
decreases. Aggregation of metal NPs in aqueous envi-
ronment has been demonstrated to depend on several 
factors, concentration included [29]. Moreover, the 
polydispersity index (pdi) increases from Fe
3
O
4
 NPs to 
Fe
3
O
4
-APTES-DAAO (Figure 6).
Cytotoxicity
The cytotoxicity of the two systems was tested on 
SKOV-3 cells with and without the substrate D-ala-
nine (1 mM). As reported in Figure 7, no significant 
differences were evident: both systems in the pres-
ence of the substrate fully depleted the ATP content at 
3.5 mU of DAAO.
Table 1. Mean bodyweight gain (%) and relative organ weight (%) following intravenous 
administration of vehicle, 100 and 20 mg/kg bodyweight of nanoparticles in mice.
EXP Group Bodyweight gain Liver Spleen Kidney
1 Vehicle (0.9% NaCl) -1.6 ± 1.9 6.6 ± 1.2 0.5 ± 0.1 1.9 ± 0.0
 Fe3O4-DAAO 100 mg/kg -3.5 ± 2.2 7.8 ± 0.3 0.6 ± 0.1 1.6 ± 0.1
2 Vehicle (NaPPi) -2.9 ± 0.4 6.7 ± 0.1 0.5 ± 0.1 1.8 ± 0.1
 Fe3O4-DAAO 20 mg/kg -3.5 ± 2.8 6.9 ± 0.2 0.5 ± 0.1 1.6 ± 0.2
Results are expressed as means ± SD.
Figure 7. Comparison of cytotoxicity, on SKOV-3, of Fe3O4-APTES-DAAO prepared with the two methods, without 
and with 1 mM D-Ala.
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In vivo study
Mice treated with 100 mg NP/kg
Immediately after the administration of NPs, and dur-
ing the following hours, all mice appeared healthy and 
no relevant behavioral alterations were observed. At 
necropsy, the liver of three out of three treated mice 
had a diffuse mild black-brown discoloration com-
pared with control mice. No significant differences in 
bodyweight gain and relative organ weights of liver, 
spleen and kidney were observed between control and 
Fe
3
O
4
-APTES-DAAO treated group (Table 1). Histo-
logically, in three out of three treated mice, intracyto-
plasmic brown granular material (consistent with iron 
pigment, as confirmed by Perls iron stain) was found in 
HE stained sections of the liver, spleen and lung, and 
only occasionally in the kidney (at level of blood vessels) 
Figure 8. Histology of liver, spleen, lung, and kidney of mice treated with vehicle (A), 100 mg/kg ([B]; EXP 1), 
and 20 mg/kg ([C]; EXP 2) of NPs (upper panel: HE; lower panel: Perls stain; scale bar = 25 μm). Brown granular 
material is evident in HE stained sections (arrowheads) of NP treated mice, consistent with iron aggregates, as 
confirmed by Perls stain (blue).
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(Figure 8). The results of the quantitative evaluation of 
the iron deposits detected in Perls iron stained sections 
of examined organs is reported in Table 2. In the liver 
the iron pigment was found mainly in the cytoplasm of 
Kupffer cells (immunostained with Iba1), but occasion-
ally also within spindle-shaped cells, likely consistent 
with hepatic sinusoidal endothelial cells (Figure 9). In 
the lung, there were moderate numbers of cells (mono-
cytes/macrophages) with intracytoplasmic iron pigment 
infiltrating the alveolar septa, throughout the pulmo-
nary parenchyma. Multifocally, intravascular up to 100 
μm in diameter iron aggregates (emboli) surrounded by 
granulocytes, were found in association with interstitial 
infiltrates of histiocytes expanding the alveolar septa 
(Figure 8). In the spleen, large numbers of histiocytes 
with intracytoplasmic iron pigment were found in the 
red pulp, marginal zone, and PALS/germinal center. 
The white pulp was affected by mild-to-moderate fol-
licular reactive hyperplasia. No iron  deposits were 
observed in the heart, and brain of treated mice.
Mice treated with 20 mg NP/kg
No relevant behavioral alterations and no significant 
differences of bodyweight gain, and relative organ 
weights of liver, spleen and kidney were observed 
between control and Fe
3
O
4
-APTES-DAAO-treated 
group (Table 1). Grossly, a moderate splenomegaly was 
observed only in one out of three treated mice. His-
tologically, in three out of three treated mice, small-
to-moderate amount of iron pigment was found in the 
liver (Kupffer cells), spleen (macrophages/histiocytes 
in the marginal zone, red pulp and PALS/germinal 
center) and rarely in the kidney (interstitial capillaries). 
In one out of three treated mice, only rare and small 
intracytoplasmic iron aggregates (monocytes/macro-
phages) were found in the lung alveolar septa (Figure 8). 
No iron deposits were observed in the heart, testis and 
brain. Reduced amount of iron-containing deposits 
were detected in liver and spleen compared with those 
found in mice treated with 100 mg NP/kg (Table 2).
Discussion
In our previous work, we designed a protocol for 
the immobilization of RgDAAO on magnetic iron 
oxide NPs for antitumor therapy (Fe
3
O
4
-APTES-
DAAO) [21]. The conjugation was performed via glu-
taraldehyde obtaining a system with an activity of 4 
U/mg NP. In this work, we improved the protocol for 
Table 2. Quantitative evaluation of iron deposits detected in Perls iron stained sections.
Group Liver Spleen Lung Kidney Brain Heart
Vehicle 0.02 ± 0.02 0.02 ± 0.00 0.05 ± 0.02 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
Fe3O4-DAAO 100 mg/kg 2.98 ± 1.11 1.40 ± 0.55 0.51 ± 0.13 0.09 ± 0.05 0.00 ± 0.00 0.00 ± 0.00
Fe3O4-DAAO 20 mg/kg 0.23 ± 0.07 0.17 ± 0,06 0.13 ± 0.08 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
Results are expressed as means ± SD.
Figure 9. Histological examination of mouse liver. (A) Brown aggregates of iron-containing NPs within the cytoplasm 
of Kupffer cells lining hepatic sinusoids (HE staining). (B) Iron-containing NPs (green) are mainly found in the 
cytoplasm of Iba1+ Kupffer cells (red, arrows) and occasionally in spindled cells (*). Nuclei stained with DAPI (cyan).
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the synthesis of Fe
3
O
4
-APTES-DAAO, enhancing the 
yield by 40%, reaching 100% of conjugated enzyme 
in term of activity and quantity. The conjugation of 
RgDAAO occurs by means of EDC and NHS and 
the reaction times are reduced by 2 h. The new system 
has an activity of 7 U/mg NP, 1.5-fold more than the 
old one (characterized by 4.5 U/mg NP). A schematic 
representation of the two protocols of conjugation is 
reported in Figure 10.
The comparison of the two systems by IR analysis 
demonstrates that all the ligands are functionalized in 
the EDC-NHS sample, whereas a small portion of them 
present free coordination ends in the glutaraldehyde 
compound (Figures 1 & 2). In light of this, we can say 
that the EDC-NHS sample higher activity in respect 
with the glutaraldehyde sample is due to a higher effi-
ciency of bound. In fact, apparently all available NH
2
 
sites are saturated with DAAO, while glutaraldehyde 
Figure 10. Schematic representation of the two DAAO conjugation methods on Fe3O4-APTES: (A) Conjugation via glutaraldehyde; 
(B) Conjugation via EDC and NHS.
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sample shows some free NH
2
 and aldehyde sites. More-
over all conjugation sites of Fe
3
O
4
 NPs are saturated, 
signifying that APTES functionalization is absolute.
DLS analysis shows that the population of Fe
3
O
4
-
APTES-DAAO is stable around a dimension of 1 
μm indicating that the enzyme conjugation process 
induces aggregation of NPs. However, more informa-
tion on the hydrodynamic diameter of the iron core, 
the magnetization capabilities and the iron content 
would allow to better compare these newly created 
particles to others.
The cytotoxicity analysis does not highlight any 
difference between the two systems; indeed, both 
completely deplete the ATP content at 3.5 mU in the 
presence of the DAAO substrate D-alanine. Worthy of 
note is that the second system employs a lower amount 
of Fe
3
O
4
 NPs, because of the higher enzymatic activity.
In the present paper, we have also evaluated the in 
vivo safety of the Fe
3
O
4
-APTES-DAAO system pro-
duced with the EDC-NHS procedure. In the first 
experiment, after intravenous injection in mice of 100 
mg NP/kg diluted in 0.9% NaCl no significant altera-
tions of behavior, bodyweight gain and relative organ 
weight of liver, spleen and kidney were observed. Histo-
logically, iron deposits were detected in the liver, spleen, 
lungs and kidneys, while none was found in the heart 
and brain. Mainly, iron deposits were found in the cyto-
plasm of monocytes/macrophages/histiocytes, indicat-
ing that most of injected particles were removed from 
blood circulation by phagocytic cells, as previously 
reported for other nanoparticles [30]. However, presence 
of intravascular iron deposits associated with interstitial 
inflammation were found in the lung, indicating that 
pulmonary embolization occurred after intravenous 
administration of aggregated NPs, as confirmed by the 
results of DLS analysis. In the spleen of mice treated 
with 100 mg/kg, reactive follicular hyperplasia was 
observed. This finding may be interpreted as an anti-
genic response, likely directed against the enzymatic 
portion of the NP system. In general, no overt adverse 
effects have been observed 24 h after intravenous 
administration of 100 mg Fe
3
O
4
-APTES-DAAO/kg, 
however, the presence of pulmonary embolization of 
iron aggregates prompted us to perform a second exper-
iment using a lower dose (20 mg NP/kg), and a dif-
ferent vehicle (NaPPi buffer instead of 0.9% NaCl) in 
order to prevent particle aggregation. No clinicopatho-
logical adverse effects were observed after intravenous 
administration of 20 mg NP/kg, and histologically, a 
dose-dependent decrease of iron deposits was found in 
the liver and spleen. In addition, absence of detectable 
iron deposits in the brain and testis (examined only for 
20 mg Fe
3
O
4
-DAAO/kg) suggests that our system is 
not able to cross biological barriers, or, at least, not in 
the absence of an external magnetic field and under 
tested conditions.
We also think that biological molecules, such as 
enzymes, polysaccharides [31,32], antibiotics, antibodies 
and nucleic acids [33], efficiently conjugated to mag-
netic NPs might constitute a category of ‘bionanopar-
ticles’ to be exploited in medical as well as industrial 
biotechnology.
Conclusion
We have improved the synthesis protocol of Fe
3
O
4
-
APTES-DAAO, reaching the highest activity allowed 
by the system. The acute cytotoxicity of the newly syn-
thesized nanoenzyme does not differ from the previ-
ously synthesized one. Moreover, no relevant adverse 
effects were observed after in vivo intravenous admin-
istration in mice of a single dose of 20 mg NP/kg bw.
Future perspective
Future aim will be the investigation of the biodistri-
bution of NPs under application of an external mag-
netic field. The ability of an external magnetic field to 
accumulate NPs in a determined area as well as that to 
make NPs crossing biological barriers will be investi-
gated. The ability of the system to destroy tumors will 
also be tested in vivo.
Moreover, we are convinced that flavoenzymes effi-
ciently conjugated to magnetic NPs could be exploited 
also in industrial biotechnology [34].
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